Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
HALO
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks StockStory - Tue Mar 24, 10:36PM CDT

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

HALO : 64.63 (+4.02%)
Halozyme Appoints David Ramsay as Interim Chief Financial Officer PR Newswire - Thu Mar 12, 7:30AM CDT

SAN DIEGO , March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer...

HALO : 64.63 (+4.02%)
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma PR Newswire - Fri Mar 6, 7:00AM CST

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens

HALO : 64.63 (+4.02%)
Halozyme to Participate in Upcoming Investor Conferences PR Newswire - Wed Feb 25, 7:30AM CST

SAN DIEGO , Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present...

HALO : 64.63 (+4.02%)
HALO
2 Reasons to Like HALO (and 1 Not So Much) StockStory - Tue Feb 24, 10:05PM CST

2 Reasons to Like HALO (and 1 Not So Much)

HALO : 64.63 (+4.02%)
HALO
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales StockStory - Tue Feb 17, 3:20PM CST

Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

HALO : 64.63 (+4.02%)
Halozyme Therapeutics: Q4 Earnings Snapshot AP - Tue Feb 17, 3:19PM CST

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 64.63 (+4.02%)
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE PR Newswire - Tue Feb 17, 3:01PM CST

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million

HALO : 64.63 (+4.02%)
ACHC
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know StockStory - Fri Feb 13, 2:50PM CST

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

ACHC : 23.39 (+2.45%)
HIMS : 20.76 (+10.54%)
PRVA : 20.57 (+2.75%)
HALO : 64.63 (+4.02%)
RDNT : 55.89 (+0.27%)
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results PR Newswire - Tue Feb 10, 3:05PM CST

SAN DIEGO , Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results...

HALO : 64.63 (+4.02%)

Barchart Exclusives

Ignore the Panic and Buy the Dip in Micron Stock, Says Bank of America Barchart - 40 minutes ago
A sharp pullback in Micron stock tied to AI efficiency fears may be creating a compelling entry point as demand fundamentals remain intact. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.